ATE138267T1 - Proliferative wirkung des leukämie- hemmungsfaktors auf satellitzellen - Google Patents

Proliferative wirkung des leukämie- hemmungsfaktors auf satellitzellen

Info

Publication number: ATE138267T1
Authority: AT; Austria
Prior art keywords: satellite cells; pct; cytokines; lif; alone
Prior art date: 1989-11-24

Application number

AT91900131T

Other languages

English (en)

Inventor

Lawrence Austin

Original Assignee

Univ Monash

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-11-24

Filing date

1990-11-20

Publication date

1996-06-15

1990-11-20 Application filed by Univ Monash filed Critical Univ Monash

1996-06-15 Application granted granted Critical

1996-06-15 Publication of ATE138267T1 publication Critical patent/ATE138267T1/de

Links

208000032839 leukemia Diseases 0.000 title abstract 2
230000005764 inhibitory process Effects 0.000 title 1
230000002062 proliferating effect Effects 0.000 title 1
102000004127 Cytokines Human genes 0.000 abstract 3
108090000695 Cytokines Proteins 0.000 abstract 3
210000001057 smooth muscle myoblast Anatomy 0.000 abstract 3
102000018233 Fibroblast Growth Factor Human genes 0.000 abstract 2
108050007372 Fibroblast Growth Factor Proteins 0.000 abstract 2
102000004889 Interleukin-6 Human genes 0.000 abstract 2
108090001005 Interleukin-6 Proteins 0.000 abstract 2
230000004069 differentiation Effects 0.000 abstract 2
229940126864 fibroblast growth factor Drugs 0.000 abstract 2
229940100601 interleukin-6 Drugs 0.000 abstract 2
210000003098 myoblast Anatomy 0.000 abstract 2
230000035755 proliferation Effects 0.000 abstract 2
NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 abstract 1
102000006747 Transforming Growth Factor alpha Human genes 0.000 abstract 1
102000009618 Transforming Growth Factors Human genes 0.000 abstract 1
108010009583 Transforming Growth Factors Proteins 0.000 abstract 1
101800004564 Transforming growth factor alpha Proteins 0.000 abstract 1
230000003213 activating effect Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Developmental Biology & Embryology (AREA)
Animal Behavior & Ethology (AREA)
Rheumatology (AREA)
Medicinal Chemistry (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)
Cardiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Vascular Medicine (AREA)
Microbiology (AREA)
Virology (AREA)
Physical Education & Sports Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Control Of Indicators Other Than Cathode Ray Tubes (AREA)
Devices For Indicating Variable Information By Combining Individual Elements (AREA)
Control Of El Displays (AREA)

AT91900131T 1989-11-24 1990-11-20 Proliferative wirkung des leukämie- hemmungsfaktors auf satellitzellen ATE138267T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
AUPJ755289		1989-11-24

Publications (1)

Publication Number	Publication Date
ATE138267T1 true ATE138267T1 (de)	1996-06-15

Family

ID=3774381

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT91900131T ATE138267T1 (de)	1989-11-24	1990-11-20	Proliferative wirkung des leukämie- hemmungsfaktors auf satellitzellen

Country Status (10)

Country	Link
US (1)	US5435999A (de)
EP (1)	EP0502081B1 (de)
JP (2)	JP3040815B2 (de)
AT (1)	ATE138267T1 (de)
AU (1)	AU624284B2 (de)
CA (1)	CA2045630A1 (de)
DE (1)	DE69027123T2 (de)
HK (1)	HK1003475A1 (de)
NO (1)	NO922008L (de)
WO (1)	WO1991007992A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5571508A (en) *	1989-12-18	1996-11-05	Amrad Corporation Limited	Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
DE69119759T2 (de) *	1990-03-20	1997-01-16	Amrad Corp Ltd	Verfahren zur steuerung der neuronentwicklung und des neuronunterhalts
WO1993012806A1 (en) *	1991-12-24	1993-07-08	Amrad Corporation Limited	A method for the treatment of tumours and sarcomas
WO1994021272A1 (en) *	1993-03-17	1994-09-29	Amrad Corporation Limited	A method for treating microbial infection in an animal by administering a composition comprising lif and a cytokine
US20020164313A1 (en) *	1995-03-16	2002-11-07	Tremblay Jacques P.	Compositions comprising preconditioned myoblasts having enhanced fusion properties
US5833978A (en) *	1995-03-16	1998-11-10	Universite Laval	Method of in vitro preconditioning healthy donor's myoblasts before transplantation thereof in compatible patients suffering of recessive myopathies like muscular dystrophy, for improving transplantation success
GB2301114A (en) *	1995-05-24	1996-11-27	Bradley Michael John Stringer	Method for controlling differentiation of precursor cells
AU706026B2 (en) *	1995-06-06	1999-06-10	Case Western Reserve University	Myogenic differentiation of human mesenchymal stem cells
US20020012657A1 (en) *	1996-10-18	2002-01-31	Jacques P. Tremblay	Method for in vitro preconditioning of myoblasts before transplantation
US20010041342A1 (en) *	1998-04-01	2001-11-15	The General Hospital Corporation, A Massachusetts Corporation	Molecular marker for muscle stem cells
US6866842B1 (en)	1998-05-01	2005-03-15	University Of Pittsburgh	Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
US7115417B1 (en)	1998-05-01	2006-10-03	Chancellor Michael B	Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof
EP1272204B1 (de)	2000-04-14	2007-06-20	University of Pittsburgh	Vermehrung des weich- sowie des knochengewebes anhand von aus muskeln stammenden vorläuferzellen, sowie damit verbundene zusammensetzungen und behandlungsformen
JP4680483B2 (ja)	2001-02-23	2011-05-11	ユニバーシティオブピッツバーグオブザコモンウェルスシステムオブハイヤーエデュケイション	組織および臓器の治療および修復に用いるための幹細胞マトリックスの迅速な調製方法
US7115399B2 (en) *	2001-07-31	2006-10-03	Allergan, Inc.	Pinna reflex assay
US7627373B2 (en)	2002-11-30	2009-12-01	Cardiac Pacemakers, Inc.	Method and apparatus for cell and electrical therapy of living tissue
CN1812800B (zh)	2003-04-25	2013-01-16	匹兹堡大学	用于促进和增强神经修复和再生的肌肉来源的细胞(mdc)
US7840263B2 (en) *	2004-02-27	2010-11-23	Cardiac Pacemakers, Inc.	Method and apparatus for device controlled gene expression
US7764995B2 (en)	2004-06-07	2010-07-27	Cardiac Pacemakers, Inc.	Method and apparatus to modulate cellular regeneration post myocardial infarct
US7828711B2 (en) *	2004-08-16	2010-11-09	Cardiac Pacemakers, Inc.	Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
US7981065B2 (en)	2004-12-20	2011-07-19	Cardiac Pacemakers, Inc.	Lead electrode incorporating extracellular matrix
US8060219B2 (en)	2004-12-20	2011-11-15	Cardiac Pacemakers, Inc.	Epicardial patch including isolated extracellular matrix with pacing electrodes
GB2433122B (en)	2005-12-10	2008-07-23	Endet Ltd	Gas sampling probe
AU2008205278B2 (en)	2007-01-11	2014-06-12	University Of Pittsburgh	Muscle derived cells for the treatment of urinary tract pathologies and methods of making and using the same
WO2010022083A2 (en)	2008-08-18	2010-02-25	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof
US9139814B2 (en) *	2008-09-22	2015-09-22	Universite Laval	Culture medium for myoblasts, precursors thereof and derivatives thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT87133B (pt) *	1987-04-02	1992-07-31	Amrad Corp Ltd	Metodo de purificacao do factor inibidor da leucemia (lif) e de composicoes farmaceuticas contendo polipeptidos com actividade do lif
AU609128B2 (en) *	1987-04-02	1991-04-26	Amrad Operations Pty. Limited	Leukaemia-inhibitory factor
DE68928914T2 (de) *	1988-08-04	1999-09-09	Amrad Corp. Ltd.	(in vitro)-vermehrung von embryonalen stammzellen unter verwendung von leukämie-inhibitionsfaktor (lif)
WO1990002183A1 (en) *	1988-08-18	1990-03-08	Genetics Institute, Inc.	Production of a novel lymphokine exhibiting differentiation inhibitory activity

1990
- 1990-11-20 AT AT91900131T patent/ATE138267T1/de not_active IP Right Cessation
- 1990-11-20 JP JP3500901A patent/JP3040815B2/ja not_active Expired - Fee Related
- 1990-11-20 AU AU68967/91A patent/AU624284B2/en not_active Ceased
- 1990-11-20 HK HK98102462A patent/HK1003475A1/en not_active IP Right Cessation
- 1990-11-20 DE DE69027123T patent/DE69027123T2/de not_active Expired - Fee Related
- 1990-11-20 CA CA002045630A patent/CA2045630A1/en not_active Abandoned
- 1990-11-20 US US07/741,522 patent/US5435999A/en not_active Expired - Fee Related
- 1990-11-20 EP EP91900131A patent/EP0502081B1/de not_active Expired - Lifetime
- 1990-11-20 WO PCT/AU1990/000556 patent/WO1991007992A1/en not_active Ceased
1992
- 1992-05-21 NO NO92922008A patent/NO922008L/no unknown
1999
- 1999-11-18 JP JP11328151A patent/JP2000128791A/ja active Pending

Also Published As

Publication number	Publication date
JP3040815B2 (ja)	2000-05-15
JP2000128791A (ja)	2000-05-09
CA2045630A1 (en)	1991-05-25
US5435999A (en)	1995-07-25
WO1991007992A1 (en)	1991-06-13
EP0502081A4 (en)	1993-05-05
HK1003475A1 (en)	1998-10-30
NO922008L (no)	1992-07-20
NO922008D0 (no)	1992-05-21
DE69027123T2 (de)	1997-04-24
AU6896791A (en)	1991-06-26
DE69027123D1 (de)	1996-06-27
EP0502081B1 (de)	1996-05-22
EP0502081A1 (de)	1992-09-09
JPH05502224A (ja)	1993-04-22
AU624284B2 (en)	1992-06-04

Legal Events

Date	Code	Title	Description
1996-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE138267T1 (de)	1996-06-15	Proliferative wirkung des leukämie- hemmungsfaktors auf satellitzellen
Willingham et al.	1972	Control of DNA synthesis and mitosis in 3T3 cells by cyclic AMP
Mayer et al.	1993	Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons—i. Effectsin vitro
Somermen et al.	1988	Effects of minocycline on fibroblast attachment and spreading
Stashenko et al.	1989	Effect of immune cytokines on bone
Vereshchagin et al.	1984	Quaternary mammalian extinctions in northern Eurasia.
ES2001967A6 (es)	1988-07-01	Un metoo para producir una proteina a partir de un cultivo de celulas.
IL128129A (en)	2006-12-31	Uses for human wnt polypeptides
PH17834A (en)	1985-01-07	Homogenous human interleukin,pharmaceutical compositions containing the same and process therefor
RU95115822A (ru)	1997-03-20	Биологические факторы и нейрональные стволовые клетки
DK546388A (da)	1989-04-02	Polypeptidvaekstfaktor fra maelk
EP0453453A4 (en)	1992-10-14	Leukaemia inhibitory factor from livestock species and use thereof to enhance implantation and development of embryonic cells
ES2151607T3 (es)	2001-01-01	Factor 12 de crecimiento y de diferenciacion.
IT8721005A0 (it)	1987-06-23	Metodo per la preservazione difogli trapiantabili di epitelio coltivato in vitro vitale.
HUT63769A (en)	1993-10-28	Process for producing pharmaceutical compositions comprising il-4 as active ingredient and suitable for treating thick tumours
US6423681B1 (en)	2002-07-23	Method of inducing formation of kidney epithelia from mesenchymal precursors
ATE342062T1 (de)	2006-11-15	Angiotensin ii zur verbesserung der befruchtung
CA2068224A1 (en)	1991-05-15	Novel potent inducers of terminal differentiation and method of use thereof
Sauder et al.	1986	Stimulation of muscle protein degradation by murine and human epidermal cytokines: relationship to thermal injury
CA2017315A1 (en)	1990-11-19	Interleukin i inhibitor
HU9202026D0 (en)	1992-09-28	Method and medical preparative for treatment of thrombocytopenie
DE69528473D1 (de)	2002-11-07	Verwendung von hepatozyten-wachstumsfaktor zur induzierung der proliferation und differenzierung von hämatopoietischen zellen
DE3879575D1 (de)	1993-04-29	Alpha-carotin zur wachstumshemmung von krebszellen.
GR3018632T3 (en)	1996-04-30	Beta-alethine use in cell culture and therapy.
EP0620736A4 (en)	1995-09-06	A method for the treatment of tumours and sarcomas.